N-Glycosylation is a common modification that controls protein folding and multiple functions of mature glycoproteins (1). This co-translational process is controlled by the activity of glycosyltransferases and glycosidases localized in the endoplasmic reticulum and Golgi compartments (2), and its importance increases with complexity of the organism (3, 4). Changes in the abundance and microheterogeneity of glycosylation have been associated with several diseases, including cancer. For example, increased core fucosylation, branching, and terminal sialylation of proteins were associated with carcinogenesis in multiple publications (5-7). In this study, we focus on the quantitative monitoring of changes in N-glycosylation of haptoglobin (Hp) 1 in patients with liver disease. Quantitative changes in protein glycosylation have been analyzed on the level of enzymatically detached N-glycans and on the level of glycopeptides, but the analyses of detached glycans are better developed. Almost all reported quantifications are based on relative quantities partly because quantitative standards are not readily accessible and because changes in relative distributions are considered more important than absolute quantities of the analytes. The only paper we are aware of reporting HPLC-based absolute quantification of glycans used a standard isolated from hen egg yolk for analysis of enzymatically detached N-glycans in rheumatoid arthritis (8).Multiple workflows for relative (semi)quantitative analysis of detached N-glycans, using various analytical techniques, were described (9 -13). Perhaps the most widely used profiling methods are normal phase HPLC of fluorescently labeled glycans (14, 15) and MALDI/TOF mass spectrometric screening of permethylated glycans (16). Chromatographic resolution of the fluorescently labeled complex glycan mixtures can be somewhat limited, although MALDI/TOF screening has From the